ArticleAcademic emergency medicine : official journal of the Society for Academic Emergency Medicine2023
Early emergency department experience with 7-day extended-release injectable buprenorphine for opioid use disorder.
Article in Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07148206 (Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
Who cites it
10 citing papers in PubMed.
- Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.JAMA network open · 2024Trial
- Article
- Brixadi for Stimulant Use Disorder: Evolving Pharmacologic Considerations and Clinical Implications.Advances in therapy · 2026Review
- Inpatient initiation of long-acting injectable buprenorphine for adolescents and young adults with opioid use disorder.Journal of substance use and addiction treatment · 2026Article
- Supporting Emergency Department Patients Experiencing Homelessness.Journal of the American College of Emergency Physicians open · 2026Article
- Implementation facilitation improves readiness for emergency department-initiated buprenorphine to treat opioid use disorder.Journal of substance use and addiction treatment · 2025Article
- Long-acting injectables for the treatment of substance use disorder: a look ahead.Expert opinion on drug delivery · 2025Article
- Opioid Use Disorder in Older Adults: a Narrative Review.Current geriatrics reports · 2025Article
- Trends and Disparities in Initiation of Buprenorphine in US Emergency Departments, 2013-2022.JAMA network open · 2024Article
- The limits of innovation: Directly addressing known challenges is necessary to improve the real-world experience of novel medications for opioid use disorder.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
As the opioid overdose epidemic escalates, there is an urgent need for treatment innovations to address both patient and clinician barriers when initiating buprenorphine in the emergency department (ED). These include insurance status, logistical challenges such as the ability to fill a prescription and transportation, concerns regarding diversion, and availability of urgent referral sites. Extended-release buprenorphine (XR-BUP) preparations such as a new 7-day injectable could potentially solve some of these issues. We describe the pharmacokinetics of a new 7-day XR-BUP formulation and the feasibility of its use in the ED setting. We report our early experiences with this medication (investigational drug CAM2038), in the context of an ongoing clinical trial entitled Emergency Department-Initiated BUP VAlidaTION (ED INNOVATION), to inform emergency clinicians as they consider incorporating this medication into their practice. The medication was approved by the European Medicines Agency in 2018 and the U.S. Food and Drug Administration in 2023 for those 18 years or older for the treatment of moderate to severe opioid use disorder (OUD). We report our experience with approximately 800 ED patients with OUD who received the 7-day XR-BUP preparation in the ED between June 2020 and July 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.